

Haematologica
HAEMATOL/2016/142406
Version 3

ENGAGE- 501: Phase 2 study of entinostat (SNDX-275) in relapsed
and refractory Hodgkin lymphoma

Connie Lee Batlevi, Yvette Kasamon, R. Gregory Bociek, Peter Lee,
Lia Gore, Amanda Copeland, Rachel Sorensen, Peter Ordentlich, Scott
Cruickshank, Lori Kunkel, Daniela Buglio, Francisco
Hernandez-Ilizaliturri, and Anas Younes

Disclosures: The drug was provided by Syndax Pharmaceuticals. CB, YK, GB, PL, AC, LG, DB, FH have no competing interests. RS, PO, SC, LK are employed at Syndax Pharmaceuticals AY with research funding from Johnson and Johnson, Novartis, Seattle Genetics, Curis; honoraria from Celgene, Bayer, Bristol Meyer Squibb, Sanofi-Aventis, Janssen, Takeda, Incyte

Contributions: CB, PO and AY wrote the paper. YK, GB, LG, DB, FH and AY performed the research and enrolled patients. YK, GB, LG, FH, AC and AY designed the research study. CB, PO, SC, RS, and KK analyzed the data. All authors assisted with critical paper revisions and approved the submitted version of the manuscript.